• PHP15 THE USE OF PATHOLOGY-RELATED PARAMETERS IN EXPLAINING THE VARIATION OF PUBLIC EXPENDITURES ON MEDICAL IMAGING

    Nov 1, 2002, 00:00

  • WD1 NHP AND 15D PERFORM WELL IN ASSESSMENT OF THE HRQOL OF HEALTHY WOMEN WITH HORMONE REPLACEMENT THERAPY

    Nov 1, 2002, 00:00

  • PCN10 COST ANALYSIS OF CAPECITABINE VERSUS 5-FU/LV FOR COLORECTAL CANCER PATIENTS IN THE NETHERLANDS

    Nov 1, 2002, 00:00

  • PNP3 SOCIO-ECONOMIC IMPACT OF CHRONIC DAILY HEADACHE IN THE GENERAL POPULATION IN FRANCE

    Nov 1, 2002, 00:00

  • PCV25 ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH ATORVASTATIN-AN ITALIAN PERSPECTIVE

    Nov 1, 2002, 00:00

  • PIN37 A COMPREHENSIVE NATURAL HISTORY MODEL OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND CERVICAL CANCER- POTENTIAL IMPACT OF AN HPV 16/18 VACCINE

    Nov 1, 2002, 00:00

  • UT3 ESTIMATING HEALTH UTILITY FROM A PHYSICAL FUNCTION ASSESSMENT IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7)

    Nov 1, 2002, 00:00

  • PCV33 COST-EFFECTIVENESS OF METHODS TO QUIT SMOKING IN FINNISH HEALTH CARE

    Nov 1, 2002, 00:00

  • PCV31 ACCEPTANCE AND RELIABILITY OF A COSTMEASUREMENT QUESTIONNAIRE IN CARDIAC REHABILITATION

    Nov 1, 2002, 00:00

  • PRK8 HEALTH RELATED QUALITY OF LIFE (HRQOL) IN CHRONIC DIALYSIS PATIENTS-A CRITICAL COMPARISON OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) AND CENTRE HEMODIALYSIS (CHD)

    Nov 1, 2002, 00:00

  • PNP4 SWITCHING AND PERSISTENCY IN A NSAID AND COX-2 SPECIFIC INHIBITOR USER POPULATION IN MANAGED CARE

    Nov 1, 2002, 00:00

  • PWM7 USING A DISCRETE CHOICE EXPERIMENT TO VALUE AN INJECTION DEVICE FOR INFERTILITY TREATMENT

    Nov 1, 2002, 00:00

  • Subject Index, Volume 5

    Nov 1, 2002, 00:00

  • PIN22 PHARMACOECONOMIC EVALUATION OF STREPTOMYCIN VERSUS ETHAMBUTOL AS PRIMARY ANTITUBERCULAR DRUGS IN LAGOS UNIVERSITY TEACHING HOSPITAL

    Nov 1, 2002, 00:00

  • PCV41 SCREENING FOR ANEURYSMS AFTER SUCCESSFUL TREATMENT FOR SUBARACHNOID HAEMORRHAGE- DO WE HAVE THE EVIDENCE?

    Nov 1, 2002, 00:00

  • PES12 BURDEN OF ATOPIC DERMATITIS IN SWITZERLAND

    Nov 1, 2002, 00:00

  • PCV4 COST-EFFECTIVENESS ANALYSIS OF N-3 POLYUNSATURED FATTY ACIDS (PUFA) AFTER MYOCARDIAL INFARCTION, FRENCH ASSESSMENT

    Nov 1, 2002, 00:00

  • PCV23 PHARMACOECONOMIC COMPARISON OF THE ANTIHYPERTENSIVE TREATMENT WITH TWO DIFFERENT ANGIOTENSINE CONVERTING ENZYME INHIBITORS- PERINDOPRIL AND ENALAPRIL

    Nov 1, 2002, 00:00

  • PCN12 IMPACT OF INNOVATIVE AND EXPENSIVE THERAPIES IN THE TREATMENT OF METASTATIC BREAST CANCER (MBC)- FOCUS ON TRASTUZUMAB (HERCEPTIN(H))

    Nov 1, 2002, 00:00

  • PRK7 PATIENTS ARE SATISFIED WITH TELEMEDICINE (HOME-CARE)

    Nov 1, 2002, 00:00

  • PMH8 COST-EFFECTIVENESS OF MIRTAZAPINE COMPARED TO FLUOXETINE IN THE TREATMENT OF MODERATE AND SEVERE DEPRESSION IN HUNGARY

    Nov 1, 2002, 00:00

  • PRK4 AN ECONOMIC MODEL OF UNSTABLE BLADDER IN BELGIUM

    Nov 1, 2002, 00:00

  • PRK5 A STRAIGHTFORWARD COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING TREATMENTS FOR OVERACTIVE BLADDER- CAN IT BE THIS SIMPLE?

    Nov 1, 2002, 00:00

  • PNP8 ADJUNCTIVE TOPIRAMATE THERAPY IN PATIENTS WITH REFRACTORY SEIZURES-A LIFETIME COST-UTILITY ANALYSIS

    Nov 1, 2002, 00:00

  • CC1 LITERATURE REVIEW OF GUIDELINES FOR CROSS-CULTURAL ADAPTATION OF HRQL MEASURES- UPDATED RESULTS

    Nov 1, 2002, 00:00

  • PCV52 LOW LEVEL OF CONSISTENCY BETWEEN QUALITATIVE (NCEP-II) AND QUANTITATIVE METHODS TO RECOMMEND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA IN INDIVIDUALS WITHOUT CORONARY HEART DISEASE

    Nov 1, 2002, 00:00

  • POD10 IMPROVEMENT IN QUALITY OF LIFE IN GROWTH HORMONE (GH) REPLACED HYPOPITUITARY ADULTS WITH GH DEFICIENCY IS CORRELATED WITH PATIENTREPORTED OUTCOMES-ANALYSIS OF THE KIMS DATABASE

    Nov 1, 2002, 00:00

  • PIN19 COST BENEFIT ANALYSIS ON VACCINATION FOR MEASLES IN JAPAN

    Nov 1, 2002, 00:00

  • PCN16 A COMPARISON OF THE COSTS OF GEMCITABINE/CISPLATIN AND GEMCITABINE/CARBOPLATIN COMBINATION REGIMENS IN THE TREATMENT OF ADVANCED NSCLC IN THE UK AND FRANCE

    Nov 1, 2002, 00:00

  • PHP17 SPANISH NATIONAL HEALTH SERVICE (NHS)- PHARMACEUTICAL CONSUMPTION AND ESTIMATION OF THE SAVING WITH GENERIC DRUG PRESCRIPTIONS

    Nov 1, 2002, 00:00

  • PIN4 COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS IN SPAIN

    Nov 1, 2002, 00:00

  • PNP17 COMPLIANCE OF TWO TREATMENTS OF ALZHEIMERS DISEASE

    Nov 1, 2002, 00:00

  • PWM5 PRELIMINARY VALIDATION OF A NEW DISEASE-SPECIFIC UTILITY MEASURE FOR ERECTILE DYSFUNCTION

    Nov 1, 2002, 00:00

  • MC2 A COST-EFFECTIVENESS ANALYSIS OF ORAL TRIPTAN THERAPIES

    Nov 1, 2002, 00:00

  • UT2 THE TRANSFORMATION OF SOCIAL PREFERENCE WEIGHTS- IMPLICATIONS FOR COST-EFFECTIVENESS

    Nov 1, 2002, 00:00

  • PCV8 ECONOMIC EVALUATION OF THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES)-AN ITALIAN CUSTOMIZATION

    Nov 1, 2002, 00:00

  • PCV5 COST IMPACT OF AMLODIPINE IN BRITISH COLUMBIA BASED ON THE PREVENT TRIAL RESULTS

    Nov 1, 2002, 00:00

  • PCN18 DERIVING A UTILITY WEIGHTED INDEX FROM CONDITION-SPECIFIC MEASURES- PRACTICAL SOLUTIONS FOR ECONOMIC EVALUTIONS

    Nov 1, 2002, 00:00

  • PIN13 FIVE-YEAR BUDGET IMPACT AND LIFETIME COST EFFECTIVENESS OF A LOPINAVIR/RITONAVIR (LVP/r) VS.A NELFINAVIR (NFV) CONTAINING REGIMEN FOR TREATMENT-NAVE PATIENTS

    Nov 1, 2002, 00:00

  • PDB1 COST-EFFECTIVENESS OF SWITCHING PATIENTS TO COMBINED GLIBENCLAMIDE AND METFORMIN (GLUCOVANCE) WHEN POORLY CONTROLLED WITH METFORMIN MONOTHERAPY-THE FRENCH PERSPECTIVE

    Nov 1, 2002, 00:00

  • PDB2 COST-EFFECTIVENESS ANALYSIS OF GLYCEMIC CONTROL WITH PIOGLITAZONE HYDROCHLORIDE FOR JAPANESE PATIENTS WITH TYPE II DIABETES

    Nov 1, 2002, 00:00

  • PNP5 DIRECT COSTS OF BACK PAIN IN THE UNITED STATES-A NATIONAL ESTIMATE

    Nov 1, 2002, 00:00

  • PES11 ECONOMIC EVALUATION OF METHOTREXATE AND CYCLOSPORIN A FOR PATIENTS WITH SEVERE PSORIASIS

    Nov 1, 2002, 00:00

  • POD8 THE COST-EFFECTIVENESS OF OSTEOGENIC PROTEIN 1 IN THE TREATMENT OF TIBIAL NONUNIONS IN THE UK AND GERMANY

    Nov 1, 2002, 00:00

  • PGS4 LOW-DOSE PPI AND STANDARD-DOSE PPI COMPARED WITH H2RA FOR MAINTENANCE THERAPY OF GERD-A COST-EFFECTIVENESS ANALYSIS USING MARKOV MODEL

    Nov 1, 2002, 00:00

  • PMH18 EVALUATION OF CLINICAL EFFICACY OF WEEKLY FLUOXETIN COMPARED WITH DAILY FLUOXETIN 40 MG IN AMBULATORY PATIENTS WITH MAJOR DEPRESSION

    Nov 1, 2002, 00:00

  • PCV30 PROBABILISTIC SENSITIVITY ANALYSIS FOR EVALUATING COST-EFFECTIVENESS IN SECONDARY PREVENTION OF ISCHEMIC EVENTS

    Nov 1, 2002, 00:00

  • PRP3 AN ANALYSIS OF THE LENGTH AND COSTS OF RESPIRATOR USE WITH OBSERVATIONAL DATA BASED ON MEDICAL RECORDS

    Nov 1, 2002, 00:00

  • PRK3 BRANDED VS GENERIC CYCLOSPORINE IN DE-NOVO KIDNEY TRANSPLANTATION-WHERE ARE THE COST SAVINGS?

    Nov 1, 2002, 00:00

  • PES16 MEDICAL OUTCOME OF GLAUCOMA TREATMENT IN FRANCE

    Nov 1, 2002, 00:00

  • PCV48 WHAT IS THE WILLINGNESS TO PAY FOR FUTURE HEALTH BENEFITS AMONG HYPERTENSIVE PATIENTS-A PILOT STUDY IN POLISH SETTING

    Nov 1, 2002, 00:00

  • PIN12 PHARMACOECONOMIC ANALYSIS OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS TREATMENT WITH TELITHROMYCIN OR CEFUROXIME-AXETIL

    Nov 1, 2002, 00:00

  • MC3 PROJECTIONS FOR COPD IN THE NETHERLANDS- HOW THE TYPE OF PROJECTION AFFECTS THE ESTIMATED GROWTH IN PREVALENCE

    Nov 1, 2002, 00:00

  • PRP4 INHALED ANTIINFLAMMATORY MEDICATION USE AND SUBSEQUENT HOSPITALIZATIONS AMONG TEXAS MEDICAID PATIENTS WITH PERSISTENT ASTHMA

    Nov 1, 2002, 00:00

  • PES1 COST EFFECTIVENESS OF PIMECROLIMUS (ELIDEL) IN THE TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS

    Nov 1, 2002, 00:00

  • PMH10 LENGTH OF STAY AND ANTIPSYCHOTIC TREATMENT COSTS OF PATIENTS WITH ACUTE PSYCHOSIS ADMITTED TO HOSPITAL- DESCRIPTION AND ASSOCIATED FACTORS- THE PSYCHOSP STUDY

    Nov 1, 2002, 00:00

  • PNP9 RETROSPECTIVE EVALUATION OF DYSPORTTM AND BOTOXTM DRUG UTILIZATION IN THE MANAGEMENT OF PATIENTS WITH CERVICAL DYSTONIA OR BLEPHAROSPASM

    Nov 1, 2002, 00:00

  • PCN17 COMPARING THE COST-EFFECTIVENESS OF 3 MCG/KG Q2W DARBEPOETIN ALFA WITH STANDARD DOSE EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES

    Nov 1, 2002, 00:00

  • PNP18 FORMULARY DECISION SUPPORT FOR INTERFERON-BETA-1A USING ANALYSIS OF CARE-SEEKING BEHAVIOR FOR MULTIPLE SCLEROSIS

    Nov 1, 2002, 00:00

  • PCV51 POSSIBILITIES OF NEW TECHNOLOGIES AMONG PATIENTS WITH HYPERTENSION- FEASIBILITY AND ACCEPTANCE OF AN EDUCATIVE INTERVENTION THROUGH SHORT MESSAGES TO THE PATIENTS CELLULAR PHONE

    Nov 1, 2002, 00:00

  • Validation of the Patient Perception of Migraine Questionnaire

    Sep 1, 2002, 00:00

  • Comparative Analysis of Two Quality-of-Life Instruments for Patients with Chronic Obstructive Pulmonary Disease

    Sep 1, 2002, 00:00

  • Bootstrap Confidence Intervals for Costs-of-Illness of Type 2 Diabetes Mellitus in Germany

    Sep 1, 2002, 00:00

  • The Cost-Effectiveness of Alternative Therapeutic Strategies for the Management of Chronic Hepatitis B in Poland

    Sep 1, 2002, 00:00

  • The Bleeding Edge of Decision Making in Managed Health Care—Kaiser-Permanente's Model for Formulary Development

    Sep 1, 2002, 00:00

  • FDA Actions against Misleading or Unsubstantiated Economic and Quality-of-Life Promotional Claims- An Analysis of Warning Letters and Notices of Violation

    Sep 1, 2002, 00:00

  • Odds Ratio, Relative Risk, Absolute Risk Reduction, and the Number Needed to Treat—Which of These Should We Use?

    Sep 1, 2002, 00:00

  • Comparing Cost-Effectiveness Analyses of Anti-Hypertensive Drug Therapy for Decision Making- Mission Impossible?

    Jul 1, 2002, 00:00

  • A Comparison of Methods for Analyzing Health-Related Quality-of-Life Measures

    Jul 1, 2002, 00:00

  • Consistent Patient-Reported Outcomes

    Jul 1, 2002, 00:00

  • Inpatient Hospital and Post-Acute Care for Vertebral Fractures in Women

    Jul 1, 2002, 00:00

  • The Regulation of Patient-Reported Outcome Claims- Need for a Flexible Standard

    Jul 1, 2002, 00:00

  • Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn

    Jul 1, 2002, 00:00

  • Conditions for the Near Equivalence of Cost-Effectiveness and Cost-Benefit Analyses

    Jul 1, 2002, 00:00

  • Modeling Costs and Cost-Effectiveness of Different CMV Management Strategies in Liver Transplant Recipients as a Support for Current and Future Decision Making

    Jul 1, 2002, 00:00

  • Formulary Development at Regence BlueShield—A Formula for Success

    Jul 1, 2002, 00:00

  • PMH17 ECONOMICS OF PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC IN OLDER PSYCHOTIC PATIENTS AND IN PATIENTS WITH BIPOLAR DISORDER

    May 1, 2002, 00:00

  • PMH10 THE BURDEN OF DEPRESSION IN CANADA

    May 1, 2002, 00:00

  • PCV30 ECONOMIC EVALUATION OF THREE MARKET LEADING HMG-CO-A REDUCTASE INHIBITORS

    May 1, 2002, 00:00

  • PAO20 TRENDS OF ANTIRESORPTIVE THERAPIES USE AMONG WOMEN WITH PREVIOUS OSTEOPOROTIC FRACTURE

    May 1, 2002, 00:00

  • PCV36 MEDICATION ADHERENCE AND HEALTH CARE UTILIZATION IN HEART FAILURE PATIENTS

    May 1, 2002, 00:00

  • PIN1 THE EFFECT OF ANTIBIOTIC USE ON RETURN VISITS FOR ACUTE RESPIRATORY TRACT INFECTIONS

    May 1, 2002, 00:00

  • PGI10 PHARMACY DISPENSING PATTERNS, COST AND HEALTHCARE UTILIZATION- A STUDY OF LANSOPRAZOLE

    May 1, 2002, 00:00

  • PIN5 COST-EFFECTIVENESS OF VACCINATING ADULT CLOSE CONTACTS WITH BOOSTRIX

    May 1, 2002, 00:00

  • PDB9 A RETROSPECTIVE ANALYSIS OF SHORT-TERM COSTS AND UTLIZATION ASSOCIATED WITH GLYCEMIC CONTROL AMONG TYPE2 DIABETIC PATIENTS WITHIN A MANAGED CARE ORGANIZATION

    May 1, 2002, 00:00

  • PIN18 THE ASSOCIATION BETWEEN HEALTH RELATED QUALITY OF LIFE AND ADHERENCE TO THERAPY IN HEPATITIS C

    May 1, 2002, 00:00

  • PCN4 RETROSPECTIVE COST ANALYSIS OF GEMZARTM IN COMBINATION WITH CISPLATIN IN NON-SMALL CELL LUNG CANCER COMPARED TO OTHER COMBINATION THERAPIES IN GERMANY

    May 1, 2002, 00:00

  • PNP6 WHAT IS IMPACT OF INSOMNIA ON MEDICAL DISORDERS, QUALITY OF LIFE AND ABSENTEEISM? A STUDY IN A FRENCH WORKING POPULATION

    May 1, 2002, 00:00

  • PHP8 PERCEPTIONS OF COUNSELING FOR OBESITY AND RELATED BARRIERS AMONG COMMUNITY PHARMACISTS IN TEXAS

    May 1, 2002, 00:00

  • PHP29 EVALUATION OF DRUGS IN A THREE-TIER PRESCRIPTION DRUG BENEFIT CO-PAYMENT PRICING STRUCTURE

    May 1, 2002, 00:00

  • PCN5 PROSPECTIVE HEALTH ECONOMIC EVALUATION OF MEDICAL CARE FOR PATIENTS WITH MALIGNANT LYMPHOMAS IN GERMANY- FIRST RESULTS

    May 1, 2002, 00:00

  • PMI19 THE USE OF PHARMACY CLAIMS DATA TO EVALUATE QUALITY OF PHARMACOLOGIC CARE FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

    May 1, 2002, 00:00

  • PMI13 STANDARD GAMBLE AND CONJOINT UTILITY WEIGHTS- VALIDITY, FEASIBILITY, AND USEFULNESS

    May 1, 2002, 00:00

  • HP6 RELATIONSHIP OF DIRECT-TO-CONSUMER ADVERTISING SPENDING AND DRUG PRICING FOR THE TOP TWENTY DRUGS FROM 1997 TO 2000- AN EXPLORATORY STUDY

    May 1, 2002, 00:00

  • PCN13 COST-EFFECTIVENESS OF RITUXIMAB IN DIFFUSE LARGE B CELL LYMPHOMA

    May 1, 2002, 00:00

  • PMI36 INCORPORATING JAPAN INTO GLOBAL OUTCOMES RESEARCH PROTOCOLS

    May 1, 2002, 00:00

  • PCV21 COST-EFFECTIVENESS OF THE FIBRATES IN THE REDUCTION OF CORONARY HEART DISEASE EVENTS

    May 1, 2002, 00:00

  • PMH42 FROM CONVENTIONAL ANTIPSYCHOTICS TO ATYPICALS AND BACK- DYNAMIC PROCESSES IN THE DIFFUSION OF NEW MEDICATIONS

    May 1, 2002, 00:00

  • PDB6 PREVENTION OF TYPE 2 DIABETES IN THE USA- COST-EFFECTIVENESS ISSUES

    May 1, 2002, 00:00

  • PHP34 ECONOMICS OF TRANSFUSION

    May 1, 2002, 00:00

  • PMI12 DEVELOPMENT OF A NUTRITION QUALITY OF LIFE MEASURE

    May 1, 2002, 00:00

  • PHP3 ASSESSING FRACTURE RISK WITH PRESCRIPTION DRUGS IN MEDICARE-ELIGIBLE PLAN MEMBERS OF A TELECOMMUNICATIONS COMPANY

    May 1, 2002, 00:00

  • CN1 ECONOMIC EVALUATION OF CAPECITABINE-DOCETAXEL COMBINATION TREATMENT OF METASTATIC BREAST CANCER- A MICRO-SIMULATION STUDY

    May 1, 2002, 00:00

  • PMH9 THE DIRECT AND INDIRECT ECONOMIC COSTS OF PSYCHOTIC DISORDERS TO BOTH PATIENTS AND CAREGIVERS

    May 1, 2002, 00:00

  • PHP13 THE ROLE OF VARIOUS FACTORS IN THE DRUG FORMULARY DECISION-MAKING PROCESS

    May 1, 2002, 00:00

  • PCN16 EXCESS MORTALITY AND COSTS ASSOCIATED WITH SERIOUS FUNGAL INFECTIONS AMONG ELDERLY CANCER PATIENTS- FINDINGS FROM LINKED SEER-MEDICARE DATA

    May 1, 2002, 00:00

  • PHP6 AN ANALYSIS OF THE EFFECT OF MANAGED CARE IMPLEMENTATION ON PRESCRIPTION DRUG UTILIZATION BY TEXAS MEDICAID CLIENTS

    May 1, 2002, 00:00

  • PIN3 COST-EFFECTIVENESS OF VACCINE DEVELOPMENT AND ENVIRONMENTAL CONTROL AGAINST DENGUE IN SOUTHEAST ASIA

    May 1, 2002, 00:00

  • PGI3 IMPACT OF PROTON PUMP INHIBITOR UTILIZATION PATTERNS ON GASTROESOPHAGEAL REFLUX DISEASE-RELATED COSTS

    May 1, 2002, 00:00

  • PHP25 WORK-RELATED COST OF EPISODIC AND CHRONIC-EPISODIC HEALTH CONDITIONS INTHE UNITED STATES- RESULTS FROM THE AMERICAN PRODUCTIVITY AUDIT

    May 1, 2002, 00:00

  • PCV5 ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES

    May 1, 2002, 00:00

  • PCV18 OVERWEIGHT AND OBESITY- THE COST TO SOCIETY AND THE ASSOCIATION WITH BODY MASS INDEX

    May 1, 2002, 00:00

  • PHP30 PRACTICAL ASPECTS OF DESIGNING AND CONDUCTING PHARMACOECONOMIC STUDIES IN JAPAN

    May 1, 2002, 00:00

  • PIN14 HEALTH RESOURCE UTILIZATION IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS

    May 1, 2002, 00:00

  • PCV12 IMPACT OF ATRIAL FIBRILLATION ON RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH UNDERLYING CARDIOVASCULAR DISEASES

    May 1, 2002, 00:00

  • PMH27 SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)- THE IMPACT OF CLINICAL AND FUNCTIONAL CHARACTERISTICS AND ANTIPSYCHOTIC MEDICATION TREATMENT ON OUTPATIENT AND INPATIENT PSYCHIATRIC UTILIZATION

    May 1, 2002, 00:00

  • PNP8 MULTIPLE SCLEROSIS- COMPLIANCE TO COPAXONE THERAPY

    May 1, 2002, 00:00

  • PMH6 RISK OF DIABETES FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS

    May 1, 2002, 00:00

  • HP7 IMPACT OF DIRECT TO CONSUMER ADVERTISING-THE CONSUMER SEARCH FOR INFORMATION

    May 1, 2002, 00:00

  • PMH15 PREVALENCE AND COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CANADIAN CLAIMS DATABASE

    May 1, 2002, 00:00

  • PHP42 AN EPIDEMIOLOGICAL EXAMINATION OF MEDICATION RESOURCE USE AND COSTS AMONG THE INSURED ELDERLY

    May 1, 2002, 00:00

  • PMI7 MODELING ON THE STOCHASTIC FRONTIER- COST OF TREATMENT FOR ACUTE DECOMPENSATED HEART FAILURE

    May 1, 2002, 00:00

  • AR1 RELATIONSHIP BETWEEN DIFFERENT MEASURES OF ASTHMA SEVERITY- PATIENT-PERCEIVED, SYMPTOM DERIVED, AND FEV1 DETERMINED SEVERITY MEASURES

    May 1, 2002, 00:00

  • PMI31 PSYCHOMETRIC PROPERTIES OF THE HEALTH RELATED QUALITY OF LIFE INSTRUMENT IN THE MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2002, 00:00

  • PDB4 OUTCOMES WITH ROSIGLITAZONE IN CLINICAL PRACTICE

    May 1, 2002, 00:00

  • PCV22 AN EVALUATION OF THE CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING HYPERLIPIDEMIC PATIENTS TO PREFERRED STATIN THERAPY IN THE U.S. DEPARTMENT OF DEFENSE

    May 1, 2002, 00:00

  • DISCLOSURE INFORMATION

    May 1, 2002, 00:00

  • PMI24 JUSTIFYING THE USE OF COST MINIMIZATION ANALYSIS- DEMONSTRATION OF COMPARATOR EQUIVALENCE

    May 1, 2002, 00:00

  • PDB14 PATIENTs PERSPECTIVE OF HYPOGLYCEMIA AS AN ADVERSE EFFECT OF ORAL ANTIDIABETIC MEDICATIONS

    May 1, 2002, 00:00

  • PES8 THE PATIENTS' PERCEPTION OF THEIR PSORIASIS AND ITS TREATMENT THROUGH A DIARY

    May 1, 2002, 00:00

  • PAO22 REFILL ADHERENCE IN OSTEOPOROTIC WOMEN WITH PRIMARY AND SECONDARY FRACTURE PREVENTION

    May 1, 2002, 00:00

  • PUK4 AN ECONOMIC MODEL OF OVERACTIVE BLADDER IN NORWAY

    May 1, 2002, 00:00

  • PHP10 USE OF HEALTH OUTCOMES DATA IN PROMOTIONAL MATERIALS

    May 1, 2002, 00:00

  • PHP9 STRATEGIES TO REDUCE PREVENTABLE DRUG-RELATED MORBIDITY

    May 1, 2002, 00:00

  • PHP14 IMPACT OF MULTI-TIERED PHARMACY BENEFITS ON PATIENT ATTITUDES AND BEHAVIOR

    May 1, 2002, 00:00

  • PMI3 DEVELOPMENT OF DESCRIPTIONS OF TREATMENTS FOR COLORECTAL CANCER FOR USE IN PREFERENCE MEASUREMENT

    May 1, 2002, 00:00

  • PCV38 MORE MEDICATIONS AND DISEASE STATES WERE RELATED TO AN INCREASE IN MEDICATION ADHERENCE AMONG PATIENTS AFTER A MYOCARDIAL INFARCTION

    May 1, 2002, 00:00

  • PAO7 COST OFFSETS ARISING FROM THE USE OF MIACALCIN- PRELIMINARY RESULTS

    May 1, 2002, 00:00

  • PUK9 VALIDATION OF THE URGENCY PERCEPTION SCALE

    May 1, 2002, 00:00

  • PCN17 SIDE EFFECTS OF CHEMOTHERAPY AMONG PATIENTS WITH OVARIAN CANCER- IMPLICATIONS FOR QUALITY OF LIFE

    May 1, 2002, 00:00

  • PIN22 PATIENT TREATMENT ACCORDING TO PRACTICE GUIDELINES IN COMMUNITY HOSPITALS COMPARED TO TEACHING HOSPITALS IN THE COMMUNITY-ACQUIRED PNEUMONIA (CAP) PROJECT

    May 1, 2002, 00:00

  • PMI5 FACTORS FOR THE VARIATION IN THE PREVALENCE OF ARTERIAL PERIPHRIAL DISEASE-STUDY IMPLICATIONS FOR OUTCOMES RESEARCH

    May 1, 2002, 00:00

  • PUK11 EFFECTS OF LONG-TERM TOLTERODINE TREATMENT ON PHYSICAL AND SYMPTOM ASPECTS OF HEALTH-RELATED QUALITY OF LIFE IN OVERACTIVE BLADDER PATIENTS

    May 1, 2002, 00:00

  • PCN20 ASSOCIATION OF INSURANCE COVERAGE AND EPIDEMIOLOGICAL RISK FACTORS ON GASTRIC CANCER SURGERY

    May 1, 2002, 00:00

  • PAO5 AN ECONOMIC MODEL FOR GASTROINTESTINAL RISK STRATIFICATION COMPARING COX-2 INHIBITORS TO TRADITIONAL NSAIDS FOR ARTHRITIS TREATMENT

    May 1, 2002, 00:00

  • PMH8 ONE YEAR HOSPITALIZATION RATES IN PATIENTS WITH SCHIZOPHRENIA DURING LONG-TERM TREATMENT WITH LONG-ACTING RISPERIDONE

    May 1, 2002, 00:00

  • PUK10 ASSESSING PATIENT SATISFACTION IN A DIALYSIS POPULATION

    May 1, 2002, 00:00

  • PMI40 THE POTENTIAL IMPORTANCE OF DATA SOURCES AND ANALYTIC APPROACHES TO THE EXTERNAL VALIDITY OF ECONOMIC STUDIES

    May 1, 2002, 00:00

  • PCV24 APPLICATION OF THE COST OF OBESITY MODEL FOR COST BENEFIT ANALYSIS (CBA) OF SIBUTRAMINE AND ORLISTAT- A THIRD PARTY PAYERs PERSPECTIVE

    May 1, 2002, 00:00

  • PCV9 ASSESSING RISK REDUCTION AND NNT AMONG TYPE 2 DIABETICS TREATED WITH FIBRIC ACID DERIVATIVES

    May 1, 2002, 00:00

  • HP8 FDA REGULATORY ACTIONS AGAINST MISLEADING OR UNSUBSTANTIATED ECONOMIC AND QUALITY-OF-LIFE CLAIMS- AN ANALYSIS OF WARNING LETTERS AND NOTICES OF VIOLATION

    May 1, 2002, 00:00

  • PMH46 MEDICATION TREATMENT PATTERNS FOLLOWING THE INITIATION OF OLANZAPINE VERSUS RISPERIDONE IN A NATURALISTIC SETTING

    May 1, 2002, 00:00

  • PIN7 EVALUATION OF THE COST-EFFECTIVENESS OF AZITHROMYCIN VERSUS AMOXICILLIN, AMOXICILLIN/CLAVULANATE, AND CLARITHROMYCIN FOR THE TREATMENT OF ACUTE SINUSITIS IN A LARGE MANAGED CARE DATABASE

    May 1, 2002, 00:00

  • PCV4 TRENDS IN THE ATTAINMENT OF CHOLESTEROL TREATMENT GOALS- EVIDENCE FROM MANAGED CARE

    May 1, 2002, 00:00

  • PRA12 ESTIMATES OF THE COST OF ASTHMA IN A EMPLOYER POPULATION

    May 1, 2002, 00:00

  • PMI2 ESTIMATING PREVALENCE AND SURVIVAL BY STAGE OF CANCER FROM THE US SEER DATABASE- COLORECTAL CANCER

    May 1, 2002, 00:00

  • PCV14 COST-EFFECTIVENESS OF THROMBOPROPHYLAXIS IN ACUTELY-ILL MEDICAL INPATIENTS

    May 1, 2002, 00:00

  • PHP51 IMPROVED QUALITY OF LIFE AND DECREASED USE OF HEALTHCARE RESOURCES ARE MAINTAINED DURING 3 YEARS OF GROWTH HORMONE (GH) SUBSTITUTION IN HYPOPITUITARY ADULTS WITH GH DEFICIENCY

    May 1, 2002, 00:00

  • PDB3 IMPROVEMENTS IN LIFE EXPECTANCY WITH LIFESTYLE CHANGES OR METFORMIN IN OVERWEIGHT, GLUCOSE INTOLERANT PATIENTS- A MODELING STUDY OF THE LONG-TERM IMPLICATIONS OF THE DIABETES PREVENTION PROGRAM

    May 1, 2002, 00:00

  • PES1 QUANTIFYING POTENTIALLY INAPPROPRIATE OPHTHALMIC BETA-BLOCKER USE IN THE MANAGEMENT OF GLAUCOMA

    May 1, 2002, 00:00

  • PUK2 UTILIZATION PATTERNS ASSOCIATED WITH TOLTERODINE IMMEDIATE RELEASE VERSUS OXYBUTYNIN IN THE MANAGEMENT OF URINARY INCONTINENCE (UI)

    May 1, 2002, 00:00

  • PGI1 EFFECTIVENESS OF MEDICAL INTERVENTIONS IN PATIENTS WITH SYMPTOMS OF GERD-A SYSTEMATIC REVIEW

    May 1, 2002, 00:00

  • CV8 FORMULARY DECISIONS- THE USE OF MULTI-ATTRIBUTE ANALYSIS-A BASELINE CASE STUDY OF PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY

    May 1, 2002, 00:00

  • PHP27 IMPACT OF A 3-TIER PHARMACY BENEFIT ON UTILIZATION PATTERNS OF TOP 10 THERAPEUTIC CLASSES- A 15-MONTH FOLLOW-UP STUDY

    May 1, 2002, 00:00

  • PHP38 IMPACT OF SELECTED CONDITIONS ON THE COSTS OF ACCIDENTS AND INJURIES

    May 1, 2002, 00:00

  • PDB15 USING SURVIVAL MODELS TO PREDICT THE START OF INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    May 1, 2002, 00:00

  • PIN16 AN ECONOMIC ASSESSMENT OF THE IMPACT OF ESCHERICHIA COLI RESISTANCE TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN THE TREATMENT OF URINARY TRACT INFECTION

    May 1, 2002, 00:00

  • PMI11 LIFE YEARS LOST DUE TO CHD

    May 1, 2002, 00:00

  • PMW9 BENIGN PROSTATIC HYPERPLASIA- CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE-RISK OF SOMNOLENCE

    May 1, 2002, 00:00

  • PHP44 HOW MUCH DOES IT COST TO DIE OF THAT? EFFECTS OF AGE AND CHRONIC ILLNESS ON HEALTHCARE COSTS AT THE END OF LIFE

    May 1, 2002, 00:00

  • PNP7 THE MIGRAINE IN FRANCE IN 2000

    May 1, 2002, 00:00

  • PRA17 CLINICAL, PUBLIC HEALTH, AND ECONOMIC ISSUES ASSOCIATED WITH SWITCHING SECOND-GENERATION ANTIHISTAMINES FROM PRESCRIPTION TO OVER-THE-COUNTER

    May 1, 2002, 00:00

  • PMI9 THE RELATIONSHIP BETWEEN DISEASE AREA AND TYPE OF ECONOMIC STUDY-DOES IT EXIST?

    May 1, 2002, 00:00

  • PGI11 EFFECT OF RABEPRAZOLE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS REPORTING INEFFECTIVE RELIEF WITH PRIOR OMEPRAZOLE OR LANSOPRAZOLE THERAPY

    May 1, 2002, 00:00

  • PMI30 A TWO-DIMENSIONAL MARKOV MODEL WITH DIFFERENT CYCLE LENGTHS FOR A CHRONIC CONDITION WITH SLOW IRREVERSIBLE DISEASE PROGRESSION AND RECURRENT PERIODS OF SEVERE SYMPTOMS

    May 1, 2002, 00:00

  • PMI32 EVALUATING THE USE OF PROBABILISTIC SENSITIVITY ANALYSIS VIA MONTE CARLO SIMULATION (MCS)- AN AUDIT OF THE HEALTH ECONOMIC LITERATURE

    May 1, 2002, 00:00

  • PRA2 PREVALENCE AND CORRELATES OF REDUCED PRODUCTIVITY ASSOCIATED WITH ALLERGIC RHINITIS IN THE WORKPLACE

    May 1, 2002, 00:00

  • PCN2 AN INTERIM COST AND OUTCOME COMPARISON ALONGSIDE A PROSPECTIVE RANDOMIZED CLINICAL TRIAL COMPARING EARLY INTENSIFICATION WITH BONE MARROW TRANSPLANTATION (BMT) TO CONVENTIONAL DOSE CHEMOTHERAPY FOR PREVIOUSLY UNTREATED PATIENTS WITH AG ...

    May 1, 2002, 00:00

  • PMW7 IDENTIFYING PATIENT AND HOSPITAL-RELATED PREDICTORS OF MATERNITY LENGTH OF STAY AND TOTAL INPATIENT CHARGES FOR OBSTETRICAL DELIVERIES IN A NATIONAL SAMPLE

    May 1, 2002, 00:00

  • PMI38 EVALUATING THE STRUCTURE OF PHARMACOECONOMIC FELLOWSHIP PROGRAMS

    May 1, 2002, 00:00

  • PCV20 A COST-EFFECTIVENESS ANALYSIS OF STATIN THERAPY IN A MANAGED CARE POPULATION

    May 1, 2002, 00:00

  • PNP5 A CONJOINT EXERCISE WITH PHYSICIANS, PATIENTS AND MCO FORMULARY MANAGERS- DRUG CHOICE TRADEOFFS IN TREATMENT OF MIGRAINE HEADACHE

    May 1, 2002, 00:00

  • PHP54 PREVENTABLE DRUG-RELATED MORBIDITY IN OLDER ADULTS IN NOVA SCOTIA, CANADA- DEVELOPMENT OF QUALITY INDICATORS

    May 1, 2002, 00:00

  • PCN6 FAMILY CAREGIVING COSTS FOR CANCER PATIENTS- A MULTI-EMPLOYER ANALYSIS

    May 1, 2002, 00:00

  • PIN4 ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ON HEALTHCARE RESOURCE UTILIZATION AND COSTS IN THE UNITED STATES

    May 1, 2002, 00:00

  • PIN19 PRESCRIBING DECISIONS IN A UTILITY MODEL

    May 1, 2002, 00:00

  • AR2 DIRECTLY ELICITED PREFERENCES COMPARED TO PREFERENCES DERIVED FROM THE SF-36 IN ADULT ASTHMATICS

    May 1, 2002, 00:00

  • PCV3 A RETROSPECTIVE, OBSERVATIONAL COHORT STUDY OF THE EFFECTS OF STATIN THERAPY ON LIPID LEVELS IN A NATURALISTIC SETTING

    May 1, 2002, 00:00

  • CV2 OUTCOMES AND COSTS OF ISCHEMIC COMPLICATIONS AND BLEEDING IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS

    May 1, 2002, 00:00

  • PMI28 ELECTRONIC DATA COLLECTION OF PATIENT-REPORTED OUTCOMES

    May 1, 2002, 00:00

  • PMH34 PSYCHOMETRIC EVALUATION OF THE MODIFIED STRAIN IN NURSING CARE ASSESSMENT SCALE

    May 1, 2002, 00:00

  • PCV1 EFFICACY OF AMLODIPINE IN REDUCING SYSTOLIC BLOOD PRESSURE- A SYSTEMATIC REVIEW OF THE LITERATURE

    May 1, 2002, 00:00

  • IN2 VALUE OF INFORMATION ANALYSIS OF THE DECISION BETWEEN CIPROFLOXACIN VS. TRIMETHOPRIM SULPHAMETHOXAZOLE FOR EMPIRICAL TREATMENT OF WOMEN WITH PYELONEPHRITIS

    May 1, 2002, 00:00

  • PMH26 A COMPARISON OF RISPERIDONE AND OLANZAPINE MENTAL HEALTH COSTS FOR MANAGED CARE PATIENTS WITH SCHIZOPHRENIA

    May 1, 2002, 00:00

  • PMH18 UTILIZATION AND COST OF RESOURCES IN BIPOLAR PATIENTS RECEIVING ATYPICAL ANTIPSYCHOTICS

    May 1, 2002, 00:00

  • PMI39 THE USE OF DRG-RELATED DATA ON KNEE PROCEDURES IN THE ANALYSIS OF UTILISATION OF RESOURCES BETWEEN BELGIAN HOSPITALS

    May 1, 2002, 00:00

  • PMI41 SATISFACTION WITH SMOKING CESSATION TREATMENTS-A SYSTEMATIC REVIEW OF THE DIMENSIONS

    May 1, 2002, 00:00

  • PMH3 ANTIPSYCHOTIC AGENTS AND THE RISK OF DEVELOPING DIABETES

    May 1, 2002, 00:00

  • PHP32 PATIENT WILLINGNESS TO PAY FOR COGNITIVE PHARMACY SERVICES IN AMBULATORY CARE SETTINGS

    May 1, 2002, 00:00

  • PNP10 THE STATE OF ANTI-EPILEPTIC DRUG PRESCRIBING- RESEARCH AND PRACTICE

    May 1, 2002, 00:00

  • PMH7 OUTCOMES AND COST OF TREATMENT WITH RISPERIDONE VERSUS OLANZAPINE AMONG PATIENTS WITH CHRONIC SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS

    May 1, 2002, 00:00

  • PCV8 CLINICAL AND ECONOMIC IMPACTS OF PHARMACIST-MANAGED ANTICOAGULATION MONITORING SERVICES

    May 1, 2002, 00:00

  • PNP9 TRIPTAN UTILIZATION PATTERNS IN A MANAGED CARE POPULATION

    May 1, 2002, 00:00

  • PHP35 ANALYZING THE CLINICAL, ECONOMIC, AND POLICY IMPACT OF INDIVIDUALIZED MEDICINE BASED ON GENETIC INFORMATION ('PHARMACOGENOMICS')

    May 1, 2002, 00:00

  • PIN13 THE IMPACT OF ANTIBIOTIC SELECTION ON TREATMENT OUTCOMES FOR ACUTE OTITIS MEDIA

    May 1, 2002, 00:00

  • PHP24 PHARMACY BENEFIT RESOURCE UTILIZATION BY ENROLLEES OF A PUBLIC EMPLOYEES INDEMNITY INSURANCE PROGRAM FOR FIVE FISCAL YEARS FROM 1996 TO 2001

    May 1, 2002, 00:00

  • PES5 COST ANALYSIS OF ISOTRETINOIN FOR SEVERE RECALCITRANT NODULAR ACNE

    May 1, 2002, 00:00

  • PCN1 LONG-TERM BENEFITS OF CHEMOPREVENTIVE TAMOXIFEN AND ROUTINE MAMMOGRAPHY SCREENING IN WOMEN WHO ARE AT INCREASED RISK OF BREAST CANCER

    May 1, 2002, 00:00

  • PCN12 AN UPDATED RISK THRESHOLD MODEL FOR G-CSF PROPHYLAXIS USE IN CANCER CHEMOTHERAPY- INCORPORATION OF PATIENT OUT-OF-POCKET AND INDIRECT COSTS

    May 1, 2002, 00:00

  • PAO21 MISSED OPPORTUNITIES IN PHARMACEUTICAL TREATMENT OF OSTEOPOROSIS IN POST-FRACTURE WOMEN

    May 1, 2002, 00:00

  • PHP47 CHILDREN IN NEED OF PHARMACARE- ANALYSIS OF MEDICATION FUNDING REQUESTS AT THE TORONTO HOSPITAL FOR SICK CHILDREN

    May 1, 2002, 00:00

  • HP4 THE IMPACT OF ADHERENCE TO OSTEOPOROSIS THERAPY ON FRACTURE RATES IN ACTUAL PRACTICE

    May 1, 2002, 00:00

  • PAO14 APPLICATION OF RASCH ANALYSIS IN COMPARISON OF SELF-ASSESSED HEALTH STATUS ACROSS TWO ARTHRITIS CONDITIONS USING A GENERIC HEALTH STATUS SURVEY

    May 1, 2002, 00:00

  • PCV37 EFFECT OF NON-ADHERENCE TO STATINS ON ASSOCIATED COST EFFECTIVENESS

    May 1, 2002, 00:00

  • PHP48 COST SENSITIVENESS AND PHYSICIAN TREATMENT CHOICES

    May 1, 2002, 00:00

  • PCN3 COLLECTION OF INFECTIOUS DISEASE AND ECONOMIC OUTCOMES FOR NON-HODGKINs LYMPHOMA AND MULTIPLE MYELOMA PATIENTS ADMITTED FOR INFECTIOUS COMPLICATIONS UTILIZING A PALMTM HANDHELD

    May 1, 2002, 00:00

  • PIN9 LONG-TERM ECONOMIC CONSEQUENCES OF ORGAN DYSFUNCTION FOLLOWING HOSPITAL DISCHARGE OF SEPSIS PATIENTS

    May 1, 2002, 00:00

  • PES11 FUNCTIONAL LIMITATIONS IN THE US ELDERLY POPULATION WITH VARYING LEVELS OF VISUAL IMPAIRMENT

    May 1, 2002, 00:00

  • PAO9 AN ECONOMIC COMPARISON BETWEEN COX-2 INHIBITORS AND CONVENTIONAL NSAIDS IN THE TREATMENT PAIN RELATED TO ARTHRITIS

    May 1, 2002, 00:00

  • MI2 COST-EFFECTIVENESS VS. COST-UTILITY ANALYSIS- DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE REALLY MATTER?

    May 1, 2002, 00:00

  • PCV33 QUALITY OF LIFE QUESTIONNAIRES VALIDATION IN ESSENTIAL HYPERTENSIVES FROM AN ECONOMICALLY DISADVANTAGED COMMUNITY

    May 1, 2002, 00:00

  • PCV6 IMPACT OF PHARMACIST-MANAGED AMBULATORY LIPID CLINIC

    May 1, 2002, 00:00

  • PMW6 COST EFFECTIVENESS MODELING COMPARING RECOMBINANT FSH WITH URINARY FSH FOR OVARIAN STIMULATION-A MULTINATIONAL EVALUATION

    May 1, 2002, 00:00

  • PMH5 EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE

    May 1, 2002, 00:00

  • PHP52 A RANDOMIZED, OPEN-LABEL PREFERENCE STUDY OF GENGRAF COMPARED TO NEORAL IN STABLE SOLID-ORGAN TRANSPLANT RECIPIENTS

    May 1, 2002, 00:00

  • MI4 THE DANGER OF IGNORING POPULATION HETEROGENEITY WHEN MARKOV MODELS ARE USED FOR COST EFFECTIVENESS ANALYSIS

    May 1, 2002, 00:00

  • PMH22 ECONOMIC OUTCOMES ASSOCIATED WITH OLANZAPINE VERSUS DIVALPROEX TREATMENT FOR ACUTE MANIA- RESULTS FROM A RANDOMIZED CLINICAL TRIAL

    May 1, 2002, 00:00

  • PGI6 EFFECT OF POSTOPERATIVE ILEUS ON LENGTH OF STAY IN COLECTOMY

    May 1, 2002, 00:00

  • CV6 COMPARING RECENT CARDIOVASCULAR MEDICATIONS USING AN NNT MODEL

    May 1, 2002, 00:00

  • PDB10 INCIDENCE, MANAGEMENT AND COST OF CARDIO-VASCULAR AND RENAL COMPLICATIONS IN FRENCH TYPE 2 DIABETIC PATIENTS

    May 1, 2002, 00:00

  • PMH32 THE IMPACT OF DULOXETINE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ON THE QUALITY OF LIFE IN DEPRESSION SCALE

    May 1, 2002, 00:00

  • PCN18 AN APPRAISAL OF TREATMENT SATISFACTION AND PATIENT PREFERENCE ASSESSMENTS IN PATIENTS DIAGNOSED WITH CANCER

    May 1, 2002, 00:00

  • NP1 INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES

    May 1, 2002, 00:00

  • PMH31 CATEGORICAL RESPONSE DEFINES TREATMENT EFFECTIVENESS OF OLANZAPINE VERSUS RISPERIDONE IN THE IMPROVEMENT OF NEGATIVE SYMPTOMS AND QUALITY OF LIFE IN SCHIZOPHRENIA

    May 1, 2002, 00:00

  • PAO16 RISK OF CLINICAL DEPRESSION IN ARTHRITIS- A WEB-BASED CO-ADMINISTRATION OF CESD-20 AND SF-36 TO A NATIONALLY REPRESENTATIVE ELDERLY SAMPLE

    May 1, 2002, 00:00

  • PGI2 THERAPEUTIC COMPARABILITY OF PROTON PUMP INHIBITORS

    May 1, 2002, 00:00

  • PMH29 THE EFFECTS OF PANAX GINSENG ON QUALITY OF LIFE- A PILOT STUDY

    May 1, 2002, 00:00

  • PUK7 DEVELOPMENT OF THE SYMPTOM FREQUENCY AND BOTHERSOMENESS SCALE FOR STRESS URINARY INCONTINENCE (SFB-SUI)

    May 1, 2002, 00:00

  • PMI8 VALIDATION OF COST ESTIMATION TECHNIQUE FOR HOSPITALIZATIONS FOR USE IN MULTINATIONAL ECONOMIC EVALUATIONS

    May 1, 2002, 00:00

  • PHP37 GENERIC PRESCRIBING INDEX- A TOOL TO PROMOTE COST-EFFECTIVE PRESCRIBING

    May 1, 2002, 00:00

  • PGI14 ASSESSMENT OF USE OF THE VETERANS AFFAIRS' CRITERIA FOR NONSTEROIDAL ANTI-INFLAMMATORY AGENTS

    May 1, 2002, 00:00

  • MI5 EXPLORING THE DERIVATION OF UTILITY VALUES USING A DISCRETE-CHOICE CONJOINT ANALYSIS METHOD-A COST-UTILITY ANALYSIS OF GEMCITABINE PLUS CISPLATIN FOR THE TREATMENT OF BLADDER CANCER

    May 1, 2002, 00:00

  • PAO2 TREATMENT PATTERNS OF CARE AND THE RISK OF SUBSEQUENT FRACTURES AMONG OSTEOPOROTIC WOMEN WITH INCIDENT FRACTURES

    May 1, 2002, 00:00

  • PAO18 CALCIUM SUPPLEMENTATION AND REDUCTION IN ASSOCIATED FRACTURES IN MEDICAID OSTEOPOROSIS PATIENTS

    May 1, 2002, 00:00

  • PMI29 PATIENT-GENERATED OUTCOMES- FAD OR HERE TO STAY?

    May 1, 2002, 00:00

  • PMI16 USE OF VARIOUS METHODS FOR COST ESTIMATION IN MULTI-NATIONAL ECONOMIC EVALUATIONS

    May 1, 2002, 00:00

  • PMH19 USING A COMMUNITY SAMPLE TO DERIVE UTILITY VALUES OF SCHIZOPHRENIA TREATMENT OUTCOMES FROM A TIME TRADE-OFF METHODOLOGY

    May 1, 2002, 00:00

  • PCV23 THE EFFECT OF -BLOCKER AND ACE INHIBITOR THERAPY ON THE RISK OF HOSPITALIZATION AND RESOURCE UTILIZATION AMONG PATIENTS WITH CHF ENROLLED IN A MANAGED CARE ORGANIZATION

    May 1, 2002, 00:00

  • PHP15 SURVIVAL RATES FOR PATIENTS RECEIVING TRANSFUSIONS IN THE UNITED STATES FROM AN ADMINISTRATIVE MANAGED CARE DATABASE

    May 1, 2002, 00:00

  • PCN7 COLORECTAL CANCER SCREENING- A COST-EFFECTIVENESS MODEL COMPARING VIRTUAL COLONOSCOPY AND CONVENTIONAL COLONOSCOPY

    May 1, 2002, 00:00

  • HP1 SUB-OPTIMAL STATIN COMPLIANCE IN PRIMARY AND SECONDARY PREVENTION POPULATIONS- SHOULD WE TARGET PATIENTS WITH THE MOST TO GAIN?

    May 1, 2002, 00:00

  • PDB11 HEALTH SERVICES COST AND UTILIZATION COMPARISONS AMONG LISPRO AND NON-LISPRO REGULAR INSULIN USERS

    May 1, 2002, 00:00

  • NP4 TOTAL HEALTHCARE EXPENDITURES FOR MIGRAINE PATIENTS ASSOCIATED WITH CHOICE OF DRUG THERAPY

    May 1, 2002, 00:00

  • PIN10 COST-UTILITY OF SELECTIVE BUPRENORPHINE SUBSTITUTION FOR METHADONE MAINTENANCE IN PREVENTING HIV TRANSMISSION

    May 1, 2002, 00:00

  • PUK3 COST EFFECTIVENESS OF INTENSIVE BEHAVIORAL MANAGEMENT VERSUS DDAVP IN PRIMARY NOCTURNAL ENURESIS

    May 1, 2002, 00:00

  • PHP17 DRUG INSURANCE TYPE AND INAPPROPRIATE PRESCRIPTIONS FOR THE ELDERLY- ANY CONNECTIONS?

    May 1, 2002, 00:00

  • PHP11 A DESCRIPTION OF DISCARDED PRESCRIPTION DRUGS

    May 1, 2002, 00:00

  • PGI13 USE OF NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN PATIENTS AT HIGH RISK FOR GASTROINTESTINAL SIDE EFFECTS IN A VETERANS AFFAIRS MEDICAL CENTER

    May 1, 2002, 00:00

  • CV7 COST-EFFECTIVENESS OF ADENOSINE AND DIPYRIDAMOLE IN TECHNETIUM-99M SESTAMIBI SINGLE PHOTON COMPUTED TOMOGRAPHY IMAGING

    May 1, 2002, 00:00

  • PCV28 A COST ANALYSIS OF 'BRIDGING THERAPY' FOR PATIENTS REQUIRING INTERRUPTION OF CHRONIC ANTICOAGULATION

    May 1, 2002, 00:00

  • PHP23 PREVENTABLE DRUG-RELATED MORBIDITY AND MORTALITY IN OLDER ADULTS- A CANADIAN COST-OF-ILLNESS MODEL

    May 1, 2002, 00:00

  • DB2 QOL INDICATORS OF SATISFACTION AND IMPACT ASSOCIATED WITH WEB-ENABLED DIABETES SELF-MANAGEMENT TOOLS

    May 1, 2002, 00:00

  • PHP53 STUDY OF SF-36V.2 IN A MONTANA NATIVE AMERICAN POPULATION

    May 1, 2002, 00:00

  • PMI1 FROM HEALTH-RELATED QOL TO UTILITY- IS THERE A WAY?

    May 1, 2002, 00:00

  • MI8 DEVELOPING A QUALITY APPRAISAL INSTRUMENT TO EVALUATE THE PEDIATRIC HEALTH ECONOMICS LITERATURE

    May 1, 2002, 00:00

  • PAO10 COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF FRACTURE IN WOMEN WITH ESTABLISHED OSTEOPOROSIS IN HONG KONG

    May 1, 2002, 00:00

  • MI6 ARE THE FRAMINGHAM-RISK EQUATIONS VALID FOR EUROPE?

    May 1, 2002, 00:00

  • PUK1 A COMPARISON OF PD AND HD PATIENT SURVIVAL ALLOWING FOR SWITCHES FROM PD TO HD

    May 1, 2002, 00:00

  • PRA13 THE COST OF ASTHMA IN CATALONIA- A DESCRIPTIVE AND MODELLING APPROACH

    May 1, 2002, 00:00

  • PHP43 FACTORS ASSOCIATED WITH OUT-OF-POCKET PRESCRIPTION DRUG COSTS

    May 1, 2002, 00:00

  • PHP45 A DECISION ANALYSIS MODEL FOR SCREENING OF HEREDITARY HEMOCHROMATOSIS

    May 1, 2002, 00:00

  • PRA10 RESOURCE UTILIZATION FOR INPATIENT ASTHMA CARE IN CHILDREN AND ADULTS- AN ANALYSIS OF HCUP DATA

    May 1, 2002, 00:00

  • CV5 COST-EFFECTIVENESS OF STATINS IN PRIMARY PREVENTION OF CHD

    May 1, 2002, 00:00

  • MI3 IMPORTANCE OF CONSIDERING SENSITIVITY AND SPECIFICITY OF SCREENING METHODS IN HEALTH ECONOMIC ANALYSES OF DIABETIC NEPHROPATHY SCREENING POLICIES

    May 1, 2002, 00:00

  • PIN24 WHAT IS THE VALUE OF WARD SUPPLY DATA FOR MONITORING ANTIBIOTIC USE IN HOSPITAL?

    May 1, 2002, 00:00

  • PUK8 VALIDATION OF THE PERCEPTION OF BLADDER CONDITION MEASURE IN OVERACTIVE BLADDER

    May 1, 2002, 00:00

  • PCV25 THE ECONOMIC IMPACTS OF TROUGH- PEAK RATIO AND LIPOPHILICITY ON COST-EFFECTIVENESS OF ACE-INHIBITOR THERAPY FOR HYPERTENSION

    May 1, 2002, 00:00

  • PMH28 IS DONEPEZIL COST-EFFECTIVE IN THE TREATMENT OF ALZHEIMER'S DISEASE (AD)?

    May 1, 2002, 00:00

  • PHP28 INTER-INSTITUTIONAL VARIABILITY IN PHARMACY COSTS, LENGTH OF STAY AND MORTALITY ASSOCIATED WITH CARDIAC TRANSPLANTATION AT ACADEMIC HEALTH CENTERS-A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2002, 00:00

  • PMI27 A UTILITY-MAXIMISATION MODEL OF CHOICE BETWEEN MEDICAL INTERVENTIONS INVOLVING RISK

    May 1, 2002, 00:00

  • PMH12 EMPLOYMENT-RELATED COSTS OF INFORMAL CAREGIVING FOR ALZHEIMER'S DISEASE PATIENTS- EFFECTS OD RIVASTIGMINE TREATMENT

    May 1, 2002, 00:00

  • PES7 ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR PREDOMINANTLY CLASSIC, SUBFOVEAL CNV SECONDARY TO AGE-RELATED MACULAR DEGENERATION

    May 1, 2002, 00:00

  • PMH44 SURVEY AND STATED PREFERENCE TECHNIQUES FOR ESTIMATING THE DEMAND FOR ALCOHOLISM MEDICATIONS

    May 1, 2002, 00:00

  • PHP26 COST-EFFECTIVENESS OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)

    May 1, 2002, 00:00

  • MH1 A ROBUST GLOBAL TREATMENT RESPONSE AVAILABLE TO OLANZAPINE-TREATED PATIENTS IS ASSOCIATED WITH MEANINGFUL IMPROVEMENT IN NEGATIVE SYMPTOMS AND QUALITY OF LIFE

    May 1, 2002, 00:00

  • PDB8 ECONOMIC COMPARISON OF SIX FIRST-LINE DRUG STRATEGIES IN TYPE 2 DIABETES USING A MONTE CARLO SIMULATION MODEL

    May 1, 2002, 00:00

  • PMH45 THE EFFECT OF SCHIZOPHRENIA SYMPTOMS ON EMPLOYMENT OUTCOMES

    May 1, 2002, 00:00

  • PCN15 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH METASTATIC COLORECTAL CANCER IN MANAGED CARE POPULATIONS- CAPECITABINE (XELODA) VERSUS COMPARISON THERAPIES

    May 1, 2002, 00:00

  • PIN6 DIRECT MEDICAL COSTS OF MANAGING AN EPISODE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) COMMUNITY ACQUIRED PNEUMONIA (CAP) IN U.S. ADULTS

    May 1, 2002, 00:00

  • PMH21 INPATIENT MEDICATION UTILIZATION AND COSTS OF RISPERIDONE, OLANZAPINE AND QUETIAPINE- A RETROSPECTIVE CHART ABSTRACTION STUDY

    May 1, 2002, 00:00

  • MH2 COMPARISON OF TREATMENT COST FOR DEPRESSION BETWEEN FLUOXETINE, PAROXETINE, SERTRALINE AND VENLAFAXINE USING MANAGED CARE CLAIMS DATA

    May 1, 2002, 00:00

  • PHP18 STOP- SMOKING CESSATION TARGET- OBSERVATORY PROGRAM, THE FRENCH PHYSICIANS PROGRESS

    May 1, 2002, 00:00

  • CN3 BEHIND THE VEIL OF IGNORANCE- ASSESSMENT OF PREFERENCES AND UTILITIES FROM MEN AT-RISK FOR PROSTATE CANCER

    May 1, 2002, 00:00

  • PAO3 MODELLED COST-UTILITY ANALYSIS OF ROFECOXIB AND TRADITIONAL NON-STEROIDAL THERAPIES FOR TREATMENT OF CHRONIC OSTEOARTHRITIS

    May 1, 2002, 00:00

  • PMI18 PERFORMING EPIDEMIOLOGICAL STUDIES IN SCHIZOPHRENIA- A PROPENSITY SCORE MODEL TO PREDICT SELECTION OF ATYPICAL ANTIPSYCHOTIC

    May 1, 2002, 00:00

  • PMH43 THE IMPACT OF A FORMULARY EXPANSION TO INCLUDE ADDITION OF SECOND-GENERATION ANTIPSYCHOTIC MEDICATIONS ON THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA

    May 1, 2002, 00:00

  • PES4 INFORMAL CAREGIVERS COSTS IN THE ELDERLY US POPULATION- A MULTIVARIATE REGRESSION MODEL OF THE VISUALLY IMPAIRED VERSUS UNIMPAIRED

    May 1, 2002, 00:00

  • MI1 HANDLING MISSING DATA IN STOCHASTIC COST-EFFECTIVENESS ANALYSIS- THE IMPACT OF IMPUTATION METHODS ON ESTIMATES OF THE PHYSICAL QUANTITIES OF MEDICAL CARE RESOURCE USE

    May 1, 2002, 00:00

  • PMI10 DANCING WITH THE DEVIL- THE IMPORTANCE OF SUB-GROUP ANALYSIS IN ECONOMIC EVALUATION

    May 1, 2002, 00:00

  • PRA4 ESTIMATION AND COMPARISON OF LOSS IN PRODUCTIVITY BY THE HUMAN CAPITAL AND FRICTION COST APPROACH IN PATIENTS WITH ASTHMA

    May 1, 2002, 00:00

  • PHP21 THERAPEUTIC INTERCHANGEABILITY OF LEVOTHYROXINE

    May 1, 2002, 00:00

  • DB4 A SYSTEMATIC ANALYSIS OF CONCOMITANT MORBIDITY AND MORTALITY IN DIABETES

    May 1, 2002, 00:00

  • PNP1 SOCIO-ECONOMIC IMPACT OF MIGRAINE IN FRANCE IN 2000

    May 1, 2002, 00:00

  • PMH38 CLINICAL COMPARABILITY OF SCHIZOPHRENIA PATIENTS SERVED AT TWO PUBLIC SETTINGS- VETERANS AFFAIRS (VA) AND NON-VA MEDICAID

    May 1, 2002, 00:00

  • PUK12 HOW RESPONSIVE IS THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q) TO CHANGES IN URGENCY, FREQUENCY, AND INCONTINENCE?

    May 1, 2002, 00:00

  • IN3 COST-EFFECTIVENESS OF NEW RAPID SCREENING TECHNOLOGIES FOR GONORRHEA IN URBAN EMERGENCY ROOM DEPARTMENTS

    May 1, 2002, 00:00

  • HP2 IS IT COST-EFFECTIVE TO IMPROVE COMPLIANCE WITH LIPID-LOWERING THERAPY?

    May 1, 2002, 00:00

  • PNP2 COST-EFFECTIVENESS OF RAPID MRI VERSUS LUMBAR X-RAY AS THE INITIAL INVESTIGATION FOR PRIMARY CARE PATIENTS WITH LOW BACK PAIN- A RANDOMIZED CONTROLLED TRIAL

    May 1, 2002, 00:00

  • PAO12 WEB-BASED HEALTH STATUS ASSESSMENT OF A NATIONALLY REPRESENTATIVE SAMPLE OF ELDERLY OSTEOARTHRITIC PATIENTS

    May 1, 2002, 00:00

  • PCV7 AN ANALYSIS OF SCREENING RATES FOR HYPERLIPIDEMIA AMONG MANAGED CARE PLAN MEMBERS PREVIOUSLY HOSPITALIZED FOR CORONARY HEART DISEASE

    May 1, 2002, 00:00

  • PMH35 LABOR SUPPLY OF POOR RESIDENTS IN METROPOLITAN MIAMI- THE ROLE OF DEPRESSION AND THE CO-MORBID EFFECTS OF DRUG USE

    May 1, 2002, 00:00

  • PMI15 MATHEMATICAL MODEL (MM) OF ANTIBIOTIC (AB) IN VITRO SUSCEPTIBILITY (SUS) OVER THE COMPLETE RANGE OF MINIMUM INHIBITORY CONCENTRATION (MIC)

    May 1, 2002, 00:00

  • PAO8 FIRST-YEAR COSTS ASSOCIATED WITH NOVEL DISEASE-MODIFYING DRUGS IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2002, 00:00

  • PMI23 THE ODDS OF BENEFIT VERSUS NON-BENEFIT OF THERAPY ASSOCIATED WITH THE NUMBER NEEDED TO TREAT

    May 1, 2002, 00:00

  • PES10 THE PSORIASIS MANAGEMENT DURATION INDUCED DIFFERENCES IN THE DISABILTY'S REPERCUSSION

    May 1, 2002, 00:00

  • PIN23 THE IMPACT OF PHYSICIAN REPORTED RISK FACTORS ON HOSPITALIZATION RATES FOR INFANTS ON PALIVIZUMAB THERAPY

    May 1, 2002, 00:00

  • PDB5 THE ECONOMIC VALUE OF NON-DIHYDROPYRIDINE VS. DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER/ACE INHIBITOR COMBINATIONS IN PATIENTS WITH TYPE-II DIABETES

    May 1, 2002, 00:00

  • NP2 EXCESSIVE COSTS RESULTING FROM PRIMARY CARE AND CHIROPRACTIC UTILIZATION OF DIAGNOSTIC IMAGING IN THE FIRST WEEK OF CARE FOR ACUTE LOW BACK PAIN

    May 1, 2002, 00:00

  • PCN11 COSTS AND CHARACTERISTICS OF PATIENTS WHO UNDERGO BONE MARROW TRANSPLANT (BMT)

    May 1, 2002, 00:00

  • PMW5 COST-EFFECTIVENESS ANALYSIS OF CURRENTLY MARKETED LONG-TERM CONTRACEPTIVES

    May 1, 2002, 00:00

  • PMI4 ASSESSING RESOURCE USE WITHIN ONCOLOGY INDICATIONS- A METHODOLOGICAL APPROACH TO CONDUCTING RETROSPECTIVE DATA ANALYSES

    May 1, 2002, 00:00

  • PES12 ANTIHISTAMINE UTILIZATION AND COSTS IN PATIENTS WITH ATOPIC DERMATITIS

    May 1, 2002, 00:00

  • PMI6 ESTIMATING THE BENEFITS OF ANTIHYPERTENSIVE THERAPY- AN ASSESSMENT OF PULSE PRESSURE

    May 1, 2002, 00:00

  • PRA15 IMPACT OF ALLERGY AND ASTHMA BOTH SEPARATELY AND CONCOMITANTLY ON LOST HOURS FROM WORK

    May 1, 2002, 00:00

  • PRA11 COST-UTILITY ANALYSIS OF MIDDLE SEVERE ASTHMA WITH SODIUM CROMOGLYCATE AND SODIUM NEDOCROMIL

    May 1, 2002, 00:00

  • PHP16 PATIENT SATISFACTION AND PHARMACEUTICAL OUTPATIENT CARE

    May 1, 2002, 00:00

  • PCV34 PATTERNS OF ANTIHYPERTENSIVE DRUG UTILIZATION AND CLINIC VISITS FOR ESSENTIAL HYPERTENSION- EVIDENCE FROM MEDICAL EXPENDITURE PANEL SURVEY, 1996

    May 1, 2002, 00:00

  • MH3 DEPRESSION IN PRIMARY CARE- TREATMENT AND RESPONSE

    May 1, 2002, 00:00

  • PUK6 A BUDGET IMPACT ANALYSIS OF EARLY REFERRAL TO A NEPHROLOGIST FOR ELDERLY MEDICARE PATIENTS WITH END-STAGE RENAL DISEASE

    May 1, 2002, 00:00

  • PIN17 PRELIMINARY RESULTS OF A U.S.-BASED STUDY TO VALIDATE THE ACUTE BRONCHITIS SYMPTOM SEVERITY SCALE

    May 1, 2002, 00:00

  • AR3 MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE GERMAN AND FRENCH HEALTHCARE SYSTEMS WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE +/- CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2002, 00:00

  • PMI14 THE DEVELOPMENT OF A SEVERITY STAGING SYSTEM FOR ECONOMIC EVALUATIONS OF THE PROGRESSION OF GLAUCOMA

    May 1, 2002, 00:00

  • PNP4 PRESCRIBING PATTERNS OF LONG-ACTING OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN IN THE VETERANS ADMINISTRATION SYSTEM

    May 1, 2002, 00:00

  • PMH13 IMPACT OF ANXIETY ON ABSENTEEISM- ESTIMATES FROM THE 1997 MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2002, 00:00

  • PHP1 AN ANALYSIS OF A HEALTHY START SMOKING CESSATION PROGRAM

    May 1, 2002, 00:00

  • PCV13 HOSPITAL TREATMENT PATTERNS AND RESOURCE UTILIZATION IN CONGESTIVE HEART FAILURE PATIENTS

    May 1, 2002, 00:00

  • PRA5 HEALTH CARE RESOURCES UTILIZATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2002, 00:00

  • PCV32 COST OF ILLNESS AND RESOURCE UTILIZATION FOR PATIENTS SUFFERING MYOCARDIAL INFARCTION, WITH AND WITHOUT DEPRESSION

    May 1, 2002, 00:00

  • PDB12 FACTORS PREDICTING SELF-RATED HEALTH AND PATIENT SATISFACTION IN A MANAGED CARE DIABETES POPULATION

    May 1, 2002, 00:00

  • PHP40 COST EFFECTIVENESS OF PATHOGEN INACTIVATION IN PLATELET TRANSFUSIONS

    May 1, 2002, 00:00

  • PRA3 COSTS OF ALLERGIC RHINITIS IN THE U.S

    May 1, 2002, 00:00

  • PHP12 CHANGING DRUG SELLER BEHAVIOR ON CHILD DIARRHEA MANAGEMENT- EFFECTIVENESS OF TRAINING PROGRAM AND IMPLICATIONS OF KNOWLEDGE-PRACTICE GAP

    May 1, 2002, 00:00

  • PRA6 ESTABLISHING THE RELIABILITY OF EVIDENCE FOR THE SIGNIFICANT IMPACT OF ALLERGIC RHINITIS ON HEALTH RELATED COSTS

    May 1, 2002, 00:00

  • PIN15 PREFERENCES AND WILLINGNESS-TO-PAY FOR HEALTH STATES PREVENTED BY PNEUMOCOCCAL CONJUGATE VACCINE

    May 1, 2002, 00:00

  • PHP46 A COST-BENEFIT ANALYSIS OF AN INPATIENT, PHARMACY-MANAGED MEDICATION ASSISTANCE PROGRAM FOR INDIGENT PATIENTS-A 3-MONTH PILOT STUDY

    May 1, 2002, 00:00

  • PRA9 COSTS AND BENEFITS ASSOCIATED WITH ADDITION OF SALMETEROL VERSUS MONTELUKAST TO INHALED CORTICOSTEROID THERAPY IN A MEDICAID ASTHMATIC POPULATION

    May 1, 2002, 00:00

  • PMH24 MODELING THE ECONOMIC IMPACT OF GALANTAMINE TREATMENT IN PATIENTS WITH ALZHEIMER'S DISEASE IN DIFFERENT HEALTH CARE SYSTEMS

    May 1, 2002, 00:00

  • CV1 NONCOMPLIANCE WITH STATIN THERAPY- LOST CLINICAL BENEFITS AND IMPLICATIONS FOR COST-EFFECTIVENESS

    May 1, 2002, 00:00

  • PMI42 DESIGN AND VALIDITY OF AUTOMATED HEALTH CARE DATA SCREENS TO DETECT IN-HOSPITAL ADVERSE DRUG EVENTS

    May 1, 2002, 00:00

  • PHP36 COST EFFECTIVENESS ANALYSIS OF PHARMACEUTICAL CARE IN A MEDICARE DRUG BENEFIT PROGRAM

    May 1, 2002, 00:00

  • PMW8 BENIGN PROSTATIC HYPERPLASIA- RECOGNITION OF THE CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE

    May 1, 2002, 00:00

  • PMH40 THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR PATIENTS IN THE CALIFORNIA MEDICAID PROGRAM

    May 1, 2002, 00:00

  • CN2 COST-UTILITY ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER

    May 1, 2002, 00:00

  • PMH33 QUALITY OF LIFE IN SCHIZOPHRENIA- THE RELATIONSHIP BETWEEN PARTICIPANT SELF-REPORT AND CLINICAL ASSESSMENT

    May 1, 2002, 00:00

  • PCV35 AN ASSESSMENT OF THE POTENTIAL UK POPULATION OF PEOPLE WITH TYPE 2 DIABETES ELIGIBLE FOR PROPHYLAXIS WITH RAMIPRIL TO PREVENT CARDIOVASCULAR EVENTS

    May 1, 2002, 00:00

  • DB3 DIABETIC FOOT ULCERS- THE ECONOMIC CONSEQUENCES OF INPATIENT ADMISSIONS OVER FIVE YEARS

    May 1, 2002, 00:00

  • CN4 COMPARISON OF TREATMENT MODALITIES IN PROSTATE CANCER PATIENTS

    May 1, 2002, 00:00

  • PGI5 COST-EFFECTIVENESS OF IV PPI'S IN THE TREATMENT OF NON-VARICEAL UPPER GI BLEEDING FOLLOWING URGENT ENDOSCOPY

    May 1, 2002, 00:00

  • PMH14 HEALTH CARE EXPENDITURES OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND POST TRAUMATIC STRESS DISORDER

    May 1, 2002, 00:00

  • PRA18 PREGNANCY OUTCOMES IN WOMEN TAKING ANTI-ASTHMATIC MEDICATIONS IN THE GEORGIA MEDICAID POPULATION

    May 1, 2002, 00:00

  • PGI7 ECONOMIC OUTCOMES OF EMPLOYER BENEFICIARIES TREATED FOR IRRITABLE BOWEL SYNDROME (IBS)

    May 1, 2002, 00:00

  • PMW4 DEVELOPING A BETTER UNDERSTANDING OF COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY (HRT)- A COMPREHENSIVE REVIEW OF ECONOMIC ANALYSIS FROM 1980 TO 2001

    May 1, 2002, 00:00

  • PES2 A DECISION-ANALYTIC MODEL TO COMPARE THE COST OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY WITH STANDARD TREATMENTS IN THE UK FOR DIFFICULT-TO-TREAT BASAL CELL CARCINOMA AND ACTINIC KERATOSIS

    May 1, 2002, 00:00

  • PIN21 SECOND-LINE THERAPY FOR OUTPATIENT TREATMENT FOR COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2002, 00:00

  • PAO17 STRENGTHS AND LIMITATIONS OF FUNCTIONAL HEALTH STATUS INSTRUMENTS FOR OSTEOARTHRITIS

    May 1, 2002, 00:00

  • PES3 TOPICAL CORITCOSTEROID AND PHYSICIAN VISIT UTILIZATION AND COSTS IN PATIENTS WITH ATOPIC DERMATITIS

    May 1, 2002, 00:00

  • PIN20 PHYSICIAN PRESCRIBING PATTERNS FOR PEDIATRIC OTITIS MEDIA IN AMBULATORY PATIENTS

    May 1, 2002, 00:00

  • PRA14 USE OF AN INTERACTIVE VOICE RESPONSE SYSTEM (IVRS) FOR LONG-TERM RESOURCE USE DATA COLLECTION

    May 1, 2002, 00:00

  • PCN19 USE OF THE EUROQOL VISUAL ANALOGUE SCALE IN ASSESSING LONGITUDINAL CHANGES IN QUALITY OF LIFE IN CANCER PATIENTS- A COMPARISON WITH SUBSCALES OF THE MEDICAL OUTCOMES SURVEY SHORT FORM-36

    May 1, 2002, 00:00

  • PCV10 BLOOD PRESSURE REDUCTION AND GAINS IN LIFE EXPECTANCY BASED UPON A MARKOV MODEL OF PRIMARY AND SECONDARY CARDIOVASCULAR EVENTS

    May 1, 2002, 00:00

  • PHP33 POLISH GUIDELINES FOR CONDUCTING BUDGET IMPACT ANALYSIS IN THEIR COMPARISON TO EXISTING GUIDANCE ON BUDGET IMPACT ANALYSIS IN OTHER COUNTRIES

    May 1, 2002, 00:00

  • CV4 CORRELATION BETWEEN NEW YORK HEART ASSOCIATION CLASSIFICATION AND PATIENT-REPORTED OUTCOMES

    May 1, 2002, 00:00

  • PAO13 VALIDATION OF A PATIENT QUESTIONNAIRE TO ASSESS OSTEOPOROSIS-RELATED ATTITUDES, KNOWLEDGE AND BEHAVIOR

    May 1, 2002, 00:00

  • PRA7 ECONOMIC CONSEQUENCES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A NATIONAL SAMPLE OF US ADULTS

    May 1, 2002, 00:00

  • PHP22 USING THE AMERICAN PRODUCTIVITY AUDIT (APA) TO INFORM EMPLOYERS ABOUT THE WORK-RELATED COST OF HEALTH CONDITIONS IN THEIR WORKFORCE

    May 1, 2002, 00:00

  • PIN2 RETROSPECTIVE ANALYSIS OF IMIPENEM/CILASTIN VERSUS PIPRACILLIN/TAZOBACTAM IN TREATMENT OF INFECTED NEUTROPENIC PATIENTS

    May 1, 2002, 00:00

  • PHP4 GENERIC NARROW THERAPEUTIC INDEX DRUG USE- 1996-1998

    May 1, 2002, 00:00

  • PHP50 HEALTH-RELATED QUALITY OF LIFE IN HEMOPHILIA AND VON WILLEBRANDs DISEASE- MEASUREMENT PROPERTIES OF THE HEALTH UTILITIES INDEX

    May 1, 2002, 00:00

  • PCV2 ADVERSE EVENTS IN CABG TRIALS- A SYSTEMATIC REVIEW AND ANALYSIS

    May 1, 2002, 00:00

  • PMI20 TRENDS IN PEDIATRIC HEALTH ECONOMIC EVALUATION- 1980 TO 1999

    May 1, 2002, 00:00

  • DB1 THE VALUE OF MULTIPLE YEARS HISTORY IN IDENTIFYING COMORBID CONDITIONS IN A RETROSPECTIVE DATA ANALYSIS

    May 1, 2002, 00:00

  • PCV11 THE COST OF WARFARIN MONITORING IN ANTICOAGULATION CLINICS- A MULTI-SITE MANAGED CARE STUDY

    May 1, 2002, 00:00

  • PNP3 COST-BENEFIT ANALYSIS OF ALMOTRIPTAN FROM A SOCIETAL PERSPECTIVE, USING CLINICAL TRIAL OUTCOMES

    May 1, 2002, 00:00

  • PMH36 IMPACT OF PRIMARY PAYER TYPE ON ACCESS TO ANTIDEPRESSANT PHARMACOTHERAPY AMONG PATIENTS DIAGNOSED WITH DEPRESSION

    May 1, 2002, 00:00

  • PMI26 FEATURES OF GOMPERTZ FUNCTIONS IN MODELING MORTALITY RATES

    May 1, 2002, 00:00

  • PDB7 FINANCIAL IMPACT OF IMPROVED DIABETES MANAGEMENT THROUGH BLOOD KETONE TESTING AND OPTIMIZED GLYCEMIC CONTROL

    May 1, 2002, 00:00

  • PRA8 COSTS AND BENEFITS ASSOCIATED WITH INITIATION OF FLUTICASONE VERSUS MONTELUKAST AS CONTROLLER THERAPY IN A MEDICAID ASTHMATIC POPULATION

    May 1, 2002, 00:00

  • PDB2 A RETROSPECTIVE COHORT STUDY OF DIABETES MELLITUS AND ANTIPSYCHOTIC TREATMENT IN THE UNITED KINGDOM

    May 1, 2002, 00:00

  • PHP2 THE EFFECT OF PREFERRED DRUG STATUS ON PATIENT SWITCHING, ADHERENCE, AND DAYS OF THERAPY

    May 1, 2002, 00:00

  • PIN8 INCIDENCE AND RELATED HEALTHCARE RESOURCE USE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN A HIGH-RISK ADULT POPULATION- A CLAIMS DATABASE ANALYSIS

    May 1, 2002, 00:00

  • MH4 ECONOMIC IMPACT OF TREATMENT OF DEMENTIA FOR GERMANY-A PROGNOSES TO 2050

    May 1, 2002, 00:00

  • PMI25 THE STATUS OF QUALITY OF LIFE DATA IN HEALTH TECHNOLOGY ASSESSMENTS- EVIDENCE FROM PUBLISHED NICE APPRAISALS

    May 1, 2002, 00:00

  • HP5 THE RELATIONSHIP OF DIRECT-TO-CONSUMER ADVERTISING AND CLINICIAN BEHAVIORAL INTENTIONS

    May 1, 2002, 00:00

  • PHP7 HORIZONTAL INEQUITY IN HEALTH CARE UTILIZATION IN JAPAN

    May 1, 2002, 00:00

  • PHP19 MEDICATION SUPPORT PROGRAM IMPROVES MEDICATION COMPLIANCE

    May 1, 2002, 00:00

  • NP3 AN ITEM ANALYSIS OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) USING CLASSICAL TEST THEORY AND ITEM RESPONSE THEORY METHODS

    May 1, 2002, 00:00

  • PCN8 COST-EFFECTIVENESS ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER

    May 1, 2002, 00:00

  • PCV27 HEALTH ECONOMIC ASSESSMENT OF THE ARCTIC SUNTM MODEL 100 FOR TEMPERATURE MANAGEMENT IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY

    May 1, 2002, 00:00

  • PMH41 REDUCTION IN LONG-ACTING BENZODIAZEPINE THERAPY AND ASSOCIATED FRACTURES IN ELDERLY MEDICAID PATIENTS

    May 1, 2002, 00:00

  • PMH1 USEFULNESS OF ELECTRONIC COMPLIANCE DATA IN AN EFFECTIVENESS TRIAL

    May 1, 2002, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169 (current)
  • 170
  • »